Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris

References

• Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–1912.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–659.
   PubMed Web of Science ®Google Scholar
• Samarasekera E, Sawyer L, Parnham J, et al. Assessment and management of psoriasis: summary of NICE guidance. BMJ. 2012;345:e6712.
   PubMed Web of Science ®Google Scholar
• Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol. 2005;53:S39–S49.
   PubMed Web of Science ®Google Scholar
• McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol. 1962;86:608–610.
   Web of Science ®Google Scholar
• Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol. 1985;121:63–67.
   PubMed Web of Science ®Google Scholar
• Guenther L, van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147:316–323.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150:1167–1173.
   PubMed Web of Science ®Google Scholar
• Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venerol. 2006;20:39–44.
   PubMed Web of Science ®Google Scholar
• Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet®) versus calcipotriol (Daivonex®) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat. 2007;18:361–365.
   PubMed Web of Science ®Google Scholar
• Bottomley JM, Taylor RS, Ryttov J. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence. Curr Med Res Opin. 2011;27:251–268.
   PubMed Web of Science ®Google Scholar
• Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20:465–471.
   PubMed Web of Science ®Google Scholar
• Langley RG, Gupta A, Papp K, et al. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology. 2011;222:148–156.
   PubMed Web of Science ®Google Scholar
• Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - A randomized phase II study. J Dermatolog Treat. 2016;27:120–127.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, Phase II study. J Clin Aesthet Dermatol. 2016;9:34–41.
   PubMedGoogle Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris - a randomized Phase III study (PSO-FAST). J Drugs Dermatol. 2015;14:1468–1477.
   PubMed Web of Science ®Google Scholar
• Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy versus gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31:119–126.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Olesen M, Villumsen J, et al. Significant reduction in psoriatic clinical signs with an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig. 2015;35:239–245.
   PubMed Web of Science ®Google Scholar
• Stein GL, Lebwohl M, Menter A, et al. Aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate is highly efficacious in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. J Drugs Dermatol. 2016;15:951–957.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Bang B, Clonier F, et al. Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation versus other corticosteroid psoriasis treatments. J Eur Acad Dermatol Venereol. 2016;30:1951–1956.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick TB. Soleil et peau. J Méd Esthétique. 1975;2:33–34.
   Google Scholar
• Hollesen Basse L, Olesen M, Lacour JP, et al. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol. 2014;134:abst 192.
   Web of Science ®Google Scholar
• Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6:413–425.
   PubMed Web of Science ®Google Scholar